News &
Publications

Contacts

Lisa Bailey
Interim Director of Communications
Director of Social Networking
215-214-3954
215-872-5846 (cell phone)
Lisa.Bailey@fccc.edu

Diana Quattrone
Director of Media Relations
215-728-7784
215-815-7828 (cell phone)
Diana.Quattrone@fccc.edu

Communications Staff

 

News

Highly-Specialized, Minimally-Invasive Surgery for Lung Cancer Allows Patient To Go Home Sooner

Video-assisted thoracic surgery offers comprehensive cancer removal compared to open surgery

PHILADELPHIA (Oct. 28, 2008) — Minimally-invasive surgery for lung cancer, called video-assisted thoracic surgery, or VATS, is a relatively new procedure performed almost exclusively at academic centers. Now, a preliminary study to be presented this month at the annual CHEST meeting in Philadelphia is giving surgeons an early look at its benefits.

Conventional or open surgery for lung cancer requires a six- to 10-inch incision, cutting the major muscles overlying the chest. The surgeon spreads the ribs apart with a retractor in order to view and gain access to the lung, sometimes even removing a portion of one rib. With open surgery or VATS, the surgeon removes either a section of the lung or the affected lobe.

VATS is performed with two to four small incisions (the main incision is only 2 inches long). Instead of spreading the ribs, the surgeon gains access to the lungs through a space between the ribs. By inserting a small camera, the surgeon has a magnified view of the organs on a monitor in the operating room.

"Anecdotally, we've observed similar outcomes with open surgery and VATS, but we've seen a significant advantage with VATS concerning quality of life matters," says Walter Scott, MD, a thoracic surgeon at Fox Chase Cancer Center, one of few surgeons in the country who performs this highly specialized surgery. "Now, we have well-analyzed comparison data that supports what we've observed in our patients."

  • The post-operative hospital stay was four days for VATS patients and seven days for open surgery patients (P<0.0001).
  • Adjusted median chest tube duration was 5 days for open surgery versus 4 days for VATS (P<0.0001) The percentage of patients with any complication was 42 percent for open surgery versus 35 percent for VATS (P=0.516).
  • Adjusted mean lymph nodes stations (#/patient) was 4.6 (open) versus 4.2 (VATS), p=0.249. Adjusted mean number of lymph nodes per patient was 18.1 (open) versus 14.7 (VATS), p=0.145.

For the study, Scott and his colleagues analyzed the records of 140 lobectomy patients who underwent VATS (74 patients) and open surgery (66 patients) for stage I non-small cell lung cancer. Five of the 74 VATS lobectomies were converted to open procedures. Operative mortality was 1/66 (1.5 percent) for open surgery and 1/74 (1.5 percent) for VATS.

"The most exciting finding is that our patients go home much sooner when they have VATS compared to open surgery," Scott says. The post-operative hospital stay was four days for VATS patients and seven days for open surgery patients.

"VATS patients also had the post-operative chest tube removed sooner than patients with open surgery," he says. Adjusted median chest tube duration was 5 days for open surgery versus 4 days for VATS. The percentage of patients with any complication was 42 percent for open surgery versus 35 percent for VATS.

Scott says the new study shows VATS allows the same comprehensive approach to removing the cancer as open surgery. "Removing all of the cancer is always our main goal which includes the removal of lymph nodes."

"Minimally invasive surgical techniques have been used for many decades, but only recently have we applied the technology to patients with lung cancer," Scott says. "This study is important in demonstrating the effectiveness and the reduced impact it can have for our patients."

Scott's co-authors include T. Salewa Oseni, MD, Philip Prest DO, Brian L Egleston PhD, James Flaherty MD and Abraham Lebenthal, MD. The authors report no disclosures.


Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach.  For more information, call 1-888-FOX CHASE or (1-888-369-2427).

Media inquiries only, please contact Diana Quattrone at 215-728-7784.

More 2008 News Releases »